Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Nov
04
Today In Oncology
HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal Club
Upcoming ASCO AI in Oncology Webinar Turns Chatbot Printouts Into Better Patient Conversations
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo